MedTrace Logo

Immunglobulin M Enriched Intra Venous Immunoglobulin (IVIG) Therapy in Adult Respiratory Distress Syndrom (ARDS) Patients

NCT02961166 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 57

Last updated 2018-04-24

No results posted yet for this study

Summary

57 patients with Adult Respiratory Distress Syndrome (ARDS) requiring Extracorporeal membrane oxygenation (ECMO) therapy were analyzed retrospectively. 28 patients had received immunglobulin M-enriched immunoglobulin therapy (IVIG); 29 patients did not receive IVIG therapy.

These patients were analyzed regarding length of stay in intensive care unit (LOS ICU), length of stay (LOS) in hospital and regarding mortality.

Conditions

  • Respiratory Distress Syndrome, Adult
  • Septic Shock

Interventions

DRUG

IgM enriched Immunoglobulins

Treatment for 3 days

Sponsors & Collaborators

  • Universität Tübingen

    collaborator OTHER

  • University Hospital Tuebingen

    lead OTHER

Principal Investigators

  • Helene A Haeberle, MD · University Hospital Tuebingen

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2016-01-31
Completion
2016-05-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02961166 on ClinicalTrials.gov